Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Mohamed E. Elsesy(Cairo University), Wael Mansour(Universität Hamburg), Susanne Burdak‐Rothkamm(University of Liverpool), Su Jung Oh‐Hohenhorst(Universität Hamburg), Christoph Oing(Universität Hamburg), Derya Tilki(Koç University), Carsten Bokemeyer(Universität Hamburg), Stefanie Meien(Universität Hamburg), Kai Rothkamm(Institute of Radiotherapy and Nuclear Medicine), Hartwig Huland(Universität Hamburg), Cordula Petersen(Universität Hamburg), Sabrina Köcher(Universität Hamburg), Anastassia Löser(University Hospital Schleswig-Holstein), Sally Mutiara(Universität Hamburg), Rudolf Schwarz(Universität Hamburg), Alexandra Zielinski(Universität Hamburg)
Cited by 21
Related Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654